Fecal human β-defensin-2 (hBD-2) levels and gut microbiota patterns in preterm neonates with different feeding patterns.
Human B-defensin-2
Intestinal microbiota pattern
Preterm neonates
Journal
Iranian journal of microbiology
ISSN: 2008-3289
Titre abrégé: Iran J Microbiol
Pays: Iran
ID NLM: 101518404
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
26
7
2019
pubmed:
26
7
2019
medline:
26
7
2019
Statut:
ppublish
Résumé
Human β-defensin-2 (hBD-2) is an essential antibacterial peptide involved in innate immunity and is expressed in breast milk and intestinal mucosa. The aim of this study was to investigate fecal hBD-2 levels and gut microbiota in preterm neonates with different feeding patterns. This study was cross-sectionally designed and included 44 preterm neonates categorized into four groups as follows: breast milk only, breast milk predominant, formula milk predominant, formula milk only. The study was conducted at the Neonatology Ward, National Center Hospital Cipto Mangunkusumo, Jakarta from November 2016 to April 2017. hBD-2 levels were measured by ELISA. Intestinal bacteria were quantified by qPCR. hBD-2 levels were significantly different between groups (one-way ANOVA, p=0.004) and the highest value of hBD-2 was found in the formula milk predominant group (344.87±61.2 ng/mL). hBD-2 levels were positively correlated with feeding pattern (Spearman correlation test, p=0.009, r=0.391). There were no significant differences in the total number of specific intestinal microbiota ( hBD-2 levels were significantly higher in the formula milk predominant group compared with the breast milk only group. Gut microbiota patterns showed that
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Human β-defensin-2 (hBD-2) is an essential antibacterial peptide involved in innate immunity and is expressed in breast milk and intestinal mucosa. The aim of this study was to investigate fecal hBD-2 levels and gut microbiota in preterm neonates with different feeding patterns.
MATERIALS AND METHODS
METHODS
This study was cross-sectionally designed and included 44 preterm neonates categorized into four groups as follows: breast milk only, breast milk predominant, formula milk predominant, formula milk only. The study was conducted at the Neonatology Ward, National Center Hospital Cipto Mangunkusumo, Jakarta from November 2016 to April 2017. hBD-2 levels were measured by ELISA. Intestinal bacteria were quantified by qPCR.
RESULTS
RESULTS
hBD-2 levels were significantly different between groups (one-way ANOVA, p=0.004) and the highest value of hBD-2 was found in the formula milk predominant group (344.87±61.2 ng/mL). hBD-2 levels were positively correlated with feeding pattern (Spearman correlation test, p=0.009, r=0.391). There were no significant differences in the total number of specific intestinal microbiota (
CONCLUSION
CONCLUSIONS
hBD-2 levels were significantly higher in the formula milk predominant group compared with the breast milk only group. Gut microbiota patterns showed that
Types de publication
Journal Article
Langues
eng
Pagination
151-159Références
J Immunol. 1999 Dec 15;163(12):6718-24
pubmed: 10586069
Eur J Clin Invest. 2000 Aug;30(8):695-701
pubmed: 10964161
Adv Exp Med Biol. 2000;478:77-93
pubmed: 11065062
Pediatr Res. 2003 Sep;54(3):393-9
pubmed: 12788986
Inflamm Bowel Dis. 2003 Jul;9(4):215-23
pubmed: 12902844
Appl Environ Microbiol. 2005 May;71(5):2318-24
pubmed: 15870317
Dig Dis Sci. 2005 Jul;50(7):1252-9
pubmed: 16047468
Appl Environ Microbiol. 2006 Apr;72(4):2359-65
pubmed: 16597930
Pediatr Res. 2007 Jan;61(1):2-8
pubmed: 17211132
Pediatr Res. 2007 Oct;62(4):510-4
pubmed: 17667844
Lancet. 2008 Jan 19;371(9608):261-9
pubmed: 18207020
Adv Food Nutr Res. 2008;54:45-80
pubmed: 18291304
BMC Microbiol. 2008 Sep 10;8:143
pubmed: 18783615
Neonatology. 2008;94(3):190-6
pubmed: 18832854
Bull World Health Organ. 2010 Jan;88(1):31-8
pubmed: 20428351
J Matern Fetal Neonatal Med. 2011 Jan;24(1):25-31
pubmed: 20569168
Genet Mol Res. 2011 Mar 29;10(1):519-25
pubmed: 21476197
Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G435-45
pubmed: 21700903
Appl Environ Microbiol. 2012 Feb;78(4):1107-12
pubmed: 22179250
Semin Perinatol. 2012 Apr;36(2):123-9
pubmed: 22414883
Reprod Sci. 2012 Jul;19(7):740-7
pubmed: 22421448
Pediatr Res. 2012 Nov;72(5):513-20
pubmed: 22902431
Front Cell Infect Microbiol. 2012 Oct 16;2:94
pubmed: 23087909
Pediatr Clin North Am. 2013 Feb;60(1):49-74
pubmed: 23178060
Clin Med Pediatr. 2009 Mar 04;3:45-54
pubmed: 23818794
Pediatr Infect Dis J. 2014 Aug;33(8):798-802
pubmed: 24503598
Reprod Health. 2013;10 Suppl 1:S1
pubmed: 24625113
Gastroenterology. 2014 Nov;147(5):1055-63.e8
pubmed: 25046162
J Pediatr (Rio J). 2015 Jan-Feb;91(1):36-43
pubmed: 25211380
Pathogens. 2013 Mar 19;2(1):177-92
pubmed: 25436887
Curr Opin Clin Nutr Metab Care. 2015 May;18(3):285-8
pubmed: 25807349
Pediatr Res. 2015 Sep;78(3):232-8
pubmed: 25992911
Pediatrics. 2016 Jan;137(1):null
pubmed: 26672023
Neonatology. 2016;109(4):239-47
pubmed: 26859305
Front Microbiol. 2017 Jun 30;8:1155
pubmed: 28713336
Semin Pediatr Surg. 2018 Feb;27(1):34-38
pubmed: 29275815
Front Microbiol. 2018 Jun 27;9:1376
pubmed: 29997594